PRETARGETED ANTI-CD45 RADIOIMMUNOTHERAPY STUDIES IN MACAQUES
猕猴中的预先靶向抗 CD45 放射免疫治疗研究
基本信息
- 批准号:8172763
- 负责人:
- 金额:$ 15.51万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2010
- 资助国家:美国
- 起止时间:2010-05-01 至 2011-04-30
- 项目状态:已结题
- 来源:
- 关键词:AffinityAntibodiesAntigen TargetingBindingBiotinBloodBlood CirculationBone Marrow Stem Cell TransplantationCellsChimeric ProteinsClinical ResearchComputer Retrieval of Information on Scientific Projects DatabaseDoseEffectivenessFundingGoalsGrantInstitutionInvestigationLow Dose RadiationLymphomaMacacaMethodsMusOrganOutcomePatientsPhaseProcessRadiationRadioactiveRadioactivityRadioimmunoconjugateRadioimmunotherapyRadioisotopesReagentRelative (related person)ResearchResearch PersonnelResourcesSafetySiteSolid NeoplasmSourceStreptavidinSystemTechniquesTherapeuticTissuesToxic effectUnited States National Institutes of HealthUrineblood forming organimprovedleukemianonhuman primatepre-clinicalprotein complextime interval
项目摘要
This subproject is one of many research subprojects utilizing the
resources provided by a Center grant funded by NIH/NCRR. The subproject and
investigator (PI) may have received primary funding from another NIH source,
and thus could be represented in other CRISP entries. The institution listed is
for the Center, which is not necessarily the institution for the investigator.
Our main goal is to improve the outcome of bone marrow (stem cell) transplantation for patients with leukemia or lymphoma by delivering supplemental radiation to target tissues using radiolabeled antibodies. The improvement of targeting methods may allow the delivery of larger doses of radioactivity from antibody to diseased cells and blood-forming organs, while delivering lower radiation doses to non-target organs, this may result in higher cure rates and fewer treatment-related toxicities. We are investigating a new technique called pretargeting which consists of a multi-step process to separate the slow distribution phase of the antibody molecule from the administration of the therapeutic radiation (radionuclide). First, a non-radioactive streptavidin (SA)-antibody or fusion protein (FP) complex capable of binding with the target antigen is administered. After maximal accumulation of the antibody/FP in the target organ, a biotin-containing clearing agent is injected. Biotin and SA have high affinity for each other, allowing the clearing agent to removes unbound antibody/FP from the bloodstream. Finally, a biotin-containing radioactive moiety with high affinity for the SA-antibody/FP complex is administered. Because of their small size, unbound molecules of radioactive reagent are rapidly cleared from the blood and excreted in the urine. This system has resulted in superior delivery of radiation to target versus nontarget organs in preclinical and clinical studies of radioimmunotherapy for solid tumors. Mouse studies using this technique with anti-CD45 antibodies also support the efficacy of this approach. Studies performed on macaques have demonstrated the safety of infusing each reagent in the three-step pretargeting process into nonhuman primates. Additional studies have documented the effectiveness of the pretargeting approach in improving the ratio of radiation delivered to target sites relative to non-target normal organs. Further investigations are ongoing to establish the optimal doses and time intervals for each step in the pretargeting process.
这个子项目是许多研究子项目中利用
资源由NIH/NCRR资助的中心拨款提供。子项目和
调查员(PI)可能从NIH的另一个来源获得了主要资金,
并因此可以在其他清晰的条目中表示。列出的机构是
该中心不一定是调查人员的机构。
我们的主要目标是通过使用放射性标记抗体向靶组织提供补充辐射来改善白血病或淋巴瘤患者的骨髓(干细胞)移植的结果。靶向方法的改进可能允许将较大剂量的放射性从抗体输送到病变细胞和造血器官,而将较低剂量的辐射输送到非靶器官,这可能会导致更高的治愈率和更少的治疗相关毒性。我们正在研究一种名为前靶向的新技术,它包括一个多步骤的过程,将抗体分子的缓慢分布阶段与治疗性辐射(放射性核素)的管理分开。首先,给予能够与靶抗原结合的非放射性链霉亲和素(SA)抗体或融合蛋白(FP)复合体。在抗体/FP在靶器官中最大限度积聚后,注射含有生物素的清除剂。生物素和SA具有很高的亲和力,允许清除剂从血液中去除未结合的抗体/FP。最后,给予SA-抗体/FP复合体具有高亲和力的含有生物素的放射性部分。由于其体积较小,放射性试剂的游离分子可以迅速从血液中清除并从尿液中排出。在实体肿瘤放射免疫治疗的临床前和临床研究中,该系统已导致向目标器官提供比非目标器官更好的辐射。将这项技术与抗CD45抗体一起使用的小鼠研究也支持了这种方法的有效性。在猕猴身上进行的研究已经证明,在三步预靶向过程中将每种试剂注入非人类灵长类动物是安全的。更多的研究证明了预靶向方法在改善相对于非靶点正常器官向目标部位提供的辐射比率方面的有效性。目前正在进行进一步的调查,以确定预先确定目标进程中每一步骤的最佳剂量和时间间隔。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Oliver W. Press其他文献
Phytohemagglutinin-induced differentiation and blastogenesis of precursor T cells from mouse bone marrow
植物血凝素诱导小鼠骨髓前体 T 细胞的分化和胚细胞发生
- DOI:
- 发表时间:
1977 - 期刊:
- 影响因子:15.3
- 作者:
Oliver W. Press;C. Rosse;James Clagett - 通讯作者:
James Clagett
Megadose sup90/supY-ibritumomab tiuxetan prior to allogeneic transplantation is effective for aggressive large B-cell lymphoma
大剂量 sup90/supY-伊布妥昔单抗替伊莫单抗在异基因移植前对侵袭性大 B 细胞淋巴瘤有效
- DOI:
10.1182/bloodadvances.2021005056 - 发表时间:
2022-01-11 - 期刊:
- 影响因子:7.100
- 作者:
Victor A. Chow;Ryan D. Cassaday;Theodore A. Gooley;Stephen D. Smith;Brenda M. Sandmaier;Damian J. Green;Johnnie J. Orozco;Sherilyn A. Tuazon;Manuela Matesan;Darrell R. Fisher;David G. Maloney;Oliver W. Press;Ajay K. Gopal - 通讯作者:
Ajay K. Gopal
Physics for practitioners: the use of radiolabeled monoclonal antibodies in B-cell non-Hodgkin's lymphoma.
物理学从业者:放射性标记单克隆抗体在 B 细胞非霍奇金淋巴瘤中的应用。
- DOI:
- 发表时间:
2000 - 期刊:
- 影响因子:0
- 作者:
Oliver W. Press - 通讯作者:
Oliver W. Press
Radioimmunotherapy-Augmented Nonmyeloablative Allogeneic Transplantation Improves Outcomes for Refractory Indolent B-Cell Non-Hodgkin Lymphoma: Results of an Adjusted Cohort Analysis
- DOI:
10.1016/j.bbmt.2013.12.087 - 发表时间:
2014-02-01 - 期刊:
- 影响因子:
- 作者:
Ryan D. Cassaday;Barry E. Storer;Mohamed L. Sorror;Brenda M. Sandmaier;Katherine A. Guthrie;Lacey M. Hedin;Jennifer E. Roden;Joseph G. Rajendran;John M. Pagel;David G. Maloney;Rainer F. Storb;Oliver W. Press;Ajay K. Gopal - 通讯作者:
Ajay K. Gopal
Investigation of Monocarbon Carboranes as Pendant Groups for Labeling Small Molecules with Astatine-211
- DOI:
10.1016/j.jmir.2019.11.017 - 发表时间:
2019-12-01 - 期刊:
- 影响因子:
- 作者:
Yawen Li;Ming-Kuan Chyan;Donald K. Hamlin;Damian J. Green;Oliver W. Press;D. Scott Wilbur - 通讯作者:
D. Scott Wilbur
Oliver W. Press的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Oliver W. Press', 18)}}的其他基金
CD38 Pretargeted Radioimmunotherapy for Myeloma
CD38 骨髓瘤预靶向放射免疫治疗
- 批准号:
8185529 - 财政年份:2011
- 资助金额:
$ 15.51万 - 项目类别:
CD38 Pretargeted Radioimmunotherapy for Myeloma
CD38 骨髓瘤预靶向放射免疫治疗
- 批准号:
8291997 - 财政年份:2011
- 资助金额:
$ 15.51万 - 项目类别:
CD38 Pretargeted Radioimmunotherapy for Myeloma
CD38 骨髓瘤预靶向放射免疫治疗
- 批准号:
8657898 - 财政年份:2011
- 资助金额:
$ 15.51万 - 项目类别:
CD38 Pretargeted Radioimmunotherapy for Myeloma
CD38 骨髓瘤预靶向放射免疫治疗
- 批准号:
8465138 - 财政年份:2011
- 资助金额:
$ 15.51万 - 项目类别:
RADIOIMMUNOTHERAPY AND EXTRACORPOREAL ADSORPTION THERAPY STUDIES IN MACAQUES
猕猴的放射免疫治疗和体外吸附治疗研究
- 批准号:
8172764 - 财政年份:2010
- 资助金额:
$ 15.51万 - 项目类别:
Bone Marrow Transplantation for Hematologic Malignancies using Novel Radioimmunot
使用新型放射免疫进行骨髓移植治疗血液系统恶性肿瘤
- 批准号:
8591380 - 财政年份:2010
- 资助金额:
$ 15.51万 - 项目类别:
Bispecific Antibody Engineering for AML RIT
AML RIT 的双特异性抗体工程
- 批准号:
8469739 - 财政年份:2009
- 资助金额:
$ 15.51万 - 项目类别:
PRETARGETED ANTI-CD45 RADIOIMMUNOTHERAPY STUDIES IN MACAQUES
猕猴中的预先靶向抗 CD45 放射免疫治疗研究
- 批准号:
7958870 - 财政年份:2009
- 资助金额:
$ 15.51万 - 项目类别:
RADIOIMMUNOTHERAPY AND EXTRACORPOREAL ADSORPTION THERAPY STUDIES IN MACAQUES
猕猴的放射免疫治疗和体外吸附治疗研究
- 批准号:
7958871 - 财政年份:2009
- 资助金额:
$ 15.51万 - 项目类别:
PHASE I SAFETY/FEASIBILITY: GENETICALLY MODIFIED AUTOLOGOUS T CELLS IN LYMPHOMA
I 期安全性/可行性:转基因自体 T 细胞治疗淋巴瘤
- 批准号:
7603429 - 财政年份:2007
- 资助金额:
$ 15.51万 - 项目类别:
相似海外基金
University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
- 批准号:
10073243 - 财政年份:2024
- 资助金额:
$ 15.51万 - 项目类别:
Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
- 批准号:
10752129 - 财政年份:2024
- 资助金额:
$ 15.51万 - 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
- 批准号:
2339201 - 财政年份:2024
- 资助金额:
$ 15.51万 - 项目类别:
Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
- 批准号:
MR/Y008693/1 - 财政年份:2024
- 资助金额:
$ 15.51万 - 项目类别:
Research Grant
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
- 批准号:
23K14783 - 财政年份:2023
- 资助金额:
$ 15.51万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
- 批准号:
23KJ0394 - 财政年份:2023
- 资助金额:
$ 15.51万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
- 批准号:
10076445 - 财政年份:2023
- 资助金额:
$ 15.51万 - 项目类别:
Grant for R&D
PLA2G2D Antibodies for Cancer Immunotherapy
用于癌症免疫治疗的 PLA2G2D 抗体
- 批准号:
10699504 - 财政年份:2023
- 资助金额:
$ 15.51万 - 项目类别:
Genetic adjuvants to elicit neutralizing antibodies against HIV
基因佐剂可引发抗艾滋病毒中和抗体
- 批准号:
10491642 - 财政年份:2023
- 资助金额:
$ 15.51万 - 项目类别:
Novel Immunogens to Elicit Broadly Cross-reactive Antibodies That Target the Hemagglutinin Head Trimer Interface
新型免疫原可引发针对血凝素头三聚体界面的广泛交叉反应抗体
- 批准号:
10782567 - 财政年份:2023
- 资助金额:
$ 15.51万 - 项目类别: